Schering-Plough and Helsinn Healthcare in palonosetron licensing agreement

Published: 2-Oct-2003

Schering-Plough Corporation and Helsinn Healthcare, of Switzerland, have agreed a license agreement under which Schering-Plough will acquire exclusive rights in select global markets to develop and commercialise Helsinn\'s palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV).


Schering-Plough Corporation and Helsinn Healthcare, of Switzerland, have agreed a license agreement under which Schering-Plough will acquire exclusive rights in select global markets to develop and commercialise Helsinn's palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Under the terms of the agreement, Schering-Plough obtains exclusive rights to develop and market palonosetron in Latin America, Australia, New Zealand and the Caribbean. The company will be responsible for product commercialisation in these markets and will pay Helsinn an upfront license fee, royalties on sales and subsequent milestone payments.

Palonosetron hydrochloride is a selective 5-HT3 receptor antagonist with strong binding affinity and an extended plasma half-life of approximately 40 hours. Results from Phase III clinical trials demonstrate that a single intravenous dose of palonosetron is effective in preventing both acute and delayed CINV in patients receiving moderately emetogenic chemotherapy. Palonosetron is the only 5-HT3 receptor antagonist to be approved for this indication by the US FDA. The product is under regulatory review in Europe.

'This is another significant step in our licensing activities for palonosetron,' said Riccardo Braglia, managing director of Helsinn Healthcare. 'Schering-Plough has a great presence in oncology in the chosen territories and we believe that palonosetron will fit very well in its portfolio and strategy.'

See more

You may also like

Distribution

Helsinn Group and Chugai Pharma renew partnership to further commercialise Akynzeo

Read more
The updated agreement aims to make Akynzeo more commercially available in the UK and Ireland

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Distribution

Helsinn Group and Chugai Pharma renew partnership to further commercialise Akynzeo

The updated agreement aims to make Akynzeo more commercially available in the UK and Ireland
Distribution

Helsinn signs distribution agreement with Immedica Pharma

This allows for the commercialisation of two cancer supportive care products indicated for the prevention of chemotherapy-induced nausea and vomiting
Ingredients

Helsinn brings cancer pain management option to China

With the help of Mundipharma China Pharmaceutical, ALOXI IV will be used for the prevention of chemotherapy-induced nausea and vomiting (CINV) in China
Research & Development

Helsinn invests €1 million in Gain Therapeutics

Swiss company will use the funding to address lysosomal storage disorders, CNS indications and additional diseases
Media

Approval of AKYNZEO oral formulation in Korea

CJ Healthcare plans to launch the oral formulation in Korea by the end of the year
Research & Development

Helsinn and the Scientific Centre of Monaco collaborate

Helsinn International Services and the Scientific Centre of Monaco (CSM), signed a collaboration agreement to support a research project aimed at developing pharmacological inhibitors for the most common form of kidney cancer
Regulatory

Orphan drug designation for AML treatment

Helsinn Group and MEI Pharma announced that Pracinostat has received orphan drug designation from the European Medicines Agency (EMA) for the treatment of acute myeloid leukemia (AML)
Subscribe now